2021-004 – Novel Treatment and Prevention of Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease

Background MetabolicSyndrome (MetS) is a pathological condition characterized by abdominal obesity,insulin resistance, hypertension, and hyperlipidemia that increases anindividual’s risk to develop heart disease, type 2 diabetes (T2D), andNon-Alcoholic Fatty Liver Disease (NAFLD). NALFD is the build-up of fat in theliver that can progress to non-alcoholic steatohepatitis (NASH) then cirrhosisor liver cancer. Globally, MetS affects about one-third of the adult populationwhile NAFLD affects about a quarter of the world’s population. Unfortunately,there are no medications approvedto treat MetS, NAFLD or NASH. Therefore, it is vital to find solutionsand methods to address the growing number of diagnoses. Typically, MetS istreated with intense diet change as well as anti-diabetic medication, which isvery similar to the regular treatment for NAFLD. While these methods arebeneficial, pharmaceutical development and repurposing may result in amedication capable in reversing both MetS and NAFLD. Technology Description A researcher atthe University of New Mexico Health Sciences Center has developed a novel treatmentfor Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome (MetS). Byrepurposing a drug utilized for inflammatory bowel disease, the researcher wasable to show that NAFLD and MetS cases improved in murine experiments.Targeting the gastrointestinal (GI) tract of MetS or NAFLD patients with thenon-steroidal, anti-inflammatory therapy, may exhibit beneficial effects on theGI tract, liver and insulin sensitivity in the patient. Gregg Banninger GBanninger@innovations.unm.edu 505-272-7908

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More